Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) shares were down 6.3% on Wednesday . The stock traded as low as $1.00 and last traded at $1.04. Approximately 820,496 shares traded hands during mid-day trading, an increase of 93% from the average daily volume of 424,750 shares. The stock had previously closed at $1.11.
Several research analysts recently weighed in on BLPH shares. ValuEngine downgraded shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th. Zacks Investment Research raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Tuesday, July 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Bellerophon Therapeutics in a research note on Wednesday, September 6th.
The firm’s 50-day moving average is $1.09 and its 200 day moving average is $1.23. The stock’s market capitalization is $36.58 million.
Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. On average, analysts expect that Bellerophon Therapeutics, Inc. will post ($1.12) earnings per share for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in shares of Bellerophon Therapeutics by 99.7% in the 1st quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after purchasing an additional 238,300 shares during the period. Susquehanna International Group LLP acquired a new position in shares of Bellerophon Therapeutics in the 2nd quarter valued at $1,316,000. Vanguard Group Inc. boosted its position in shares of Bellerophon Therapeutics by 52.6% in the 2nd quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after purchasing an additional 211,111 shares during the period. Finally, Goldman Sachs Group Inc. acquired a new position in shares of Bellerophon Therapeutics in the 1st quarter valued at $125,000. Institutional investors and hedge funds own 45.85% of the company’s stock.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.